Top
Mucopolysaccharidosis type I (MPS I) - Healing Genes
1238
post-template-default,single,single-post,postid-1238,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Mucopolysaccharidosis type I (MPS I)

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

RGX-111 Gene Therapy in Patients With MPS I

A Phase I Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of RGX-111 in Subjects With MPS I


Phase 1

DESCRIPTION:

Doctors at Children’s Hospital of Philadelphia and the University of Pennsylvania seek patients with Mucopolysaccharidosis type I (MPS I) to trial therapeutic gene therapy. The therapy uses a harmless virus to deliver a deliver a functional copy of the α-L-iduronidase (IDUA) gene to the central nervous system, to correct its deficiency in MPS I patients.

Study participants will receive the investigatory treatment via a single infusion to the central nervous system while under anesthesia. Follow up will require lab testing every few weeks for 2 years, with visits less frequent in the second year.


PATIENT MUST:

  • Be 6years of age or older
  • Have documented evidence of early- stage neurocognitive deficit due to MPS I
  • Be able to receive immunosuppressive therapy in conjunction with the investigative therapy

THE STUDY INVOLVES:

  1. Screening to confirm acceptance to the study.
  2. Injection of the therapy, under anesthesia, guided by CT into the spinal fluid.
  3. Close observation immediately after the treatment.
  4. Follow up for 2 years with weekly, then monthly check-ins, spacing out to twice a year.

LOCATIONS & CONTACTS:
The trial will take place at the Children’s Hospital of Philadelphia, PA. Map.

Contact:
Patient Advocacy  |  866-860-0117  |  [email protected]

SPONSORS:
Regenxbio Inc.

 

Or go online:
https://clinicaltrials.gov/ct2/show/NCT03580083

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader